trial

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

NCTId NCT00363376
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 42 (actual)
Sponsored by Lindner Center of HOPE
Primary completion 2011-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-01
Primary completion
2011-02
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
zonisamideOlanzapine

Sponsors

Lindner Center of HOPELead Sponsor
Eli Lilly and CompanyCollaborator
University of CincinnatiCollaborator

Investigators

1
Susan McElroy, MDPrincipal Investigator

Sites

1 total
Mason, United States

Linked catalysts

1
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain — primary completion2011-02

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE3
Primary Completion Date
2011-02
Status
COMPLETED
relationships
The graph out of here
drug
zonisamide
drug
Olanzapine
drug
lead_sponsor
Lindner Center of HOPE
company
collaborator
Eli Lilly and Company
company
University of Cincinnati
company
indication
Bipolar Disorder
indication
Weight Gain
indication
Weight Gain
indication
investigator
Susan McElroy, MD
person